Advertisement

Topics

Latest "Patient Privacy Rights Foundation" News Stories

01:06 EST 19th December 2018 | BioPortfolio

Here are the most relevant search results for "Patient Privacy Rights Foundation" found in our extensive news archives from over 250 global news sources.

More Information about Patient Privacy Rights Foundation on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Patient Privacy Rights Foundation for you to read. Along with our medical data and news we also list Patient Privacy Rights Foundation Clinical Trials, which are updated daily. BioPortfolio also has a large database of Patient Privacy Rights Foundation Companies for you to search.

Showing "Patient Privacy Rights Foundation" News Articles 1–25 of 13,000+

Wednesday 19th December 2018

Russia Neuromodulation Procedures Outlook to 2025 [Report Updated: 15112018] Prices from USD $2546

Russia Neuromodulation Procedures Outlook to 2025SummaryGlobalData's new report, Russia Neuromodulation Procedures Outlook to 2025, provides key procedures data on the Russia Neuromodulation Procedures. The report provides procedure volumes within market segments Deep Brain Stimulators Procedures, Gastric Electric Stimulators Procedures, Peripheral Nerve Stimulators Procedures, Sacral Nerve Stimu...


Italy Airway and Anesthesia Procedures Outlook to 2025 [Report Updated: 01102018] Prices from USD $2546

Italy Airway and Anesthesia Procedures Outlook to 2025SummaryGlobalData's new report, Italy Airway and Anesthesia Procedures Outlook to 2024, provides key procedures data on the Italy Airway and Anesthesia Procedures. The report provides procedure volumes within market segments Airway Management Procedures, Anesthesia Circuit Procedures, Anesthesia Mask Procedures, Breathing Bag Procedures, Breat...

Tuesday 18th December 2018

EU5 Hydrocephalus Shunting Procedures Outlook to 2025 [Report Updated: 01122018] Prices from USD $3396

EU5 Hydrocephalus Shunting Procedures Outlook to 2025SummaryGlobalData's new report, EU5 Hydrocephalus Shunting Procedures Outlook to 2025, provides key procedures data on the EU5 Hydrocephalus Shunting Procedures. The report provides procedure volumes within market segments New Hydrocephalus Shunts Procedures and Revision Hydrocephalus Shunts Procedures.The data in the report is derived from dyn...


Opinion: There’s no question that the doctor-patient relationship is sick in some ways, but coordinated care teams could help to heal it. https://buff.ly/2UXXrAr 

Opinion: There’s no question that the doctor-patient relationship is sick in some ways, but coordinated care teams could help to heal it. https://buff.ly/2UXXrAr 

Alterations in serum amino-acid profile in the progression of colorectal cancer: associations with systemic inflammation, tumour stage and patient survival

Civitas (CIVI) Alert: Johnson Fistel Investigates Proposed Sale of Civitas Solutions, Inc. ...

SAN DIEGO, Dec. 18, 2018 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Civitas Read more...

Australia Crown and Bridge Procedures Outlook to 2025 [Report Updated: 01092018] Prices from USD $2546

Australia Crown and Bridge Procedures Outlook to 2025SummaryGlobalData's new report, Australia Crown and Bridge Procedures Outlook to 2025, provides key procedures data on the Australia Dental Crown and Bridge Procedures. The report provides procedure volumes within market segment Dental Crown and Bridge Procedures.The data in the report is derived from dynamic market forecast models. GlobalData ...

Anji Pharmaceuticals Licenses Regional Rights to a Clinical Asset from Global Pharma

Anji Pharmaceuticals, Inc. (“Anji” or “the Company”) announced today it has licensed pradigastat, an inhibitor of acyl coA: diacylglycerol acyl transferase (DGAT1), from Novartis (NYSE: NVS). Pradigastat is a well-characterized molecule which has progressed to Phase 3 clinical testing. Anji has secured rights to pursue new indications for pradigast...

Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy

Increased bone marrow CD56bright natural killer cells at 30 days after allogeneic stem cell transplantation associated with adverse patient outcome

New RNA sequencing strategy to study gut microbiome activity

Researchers have developed a high-throughput RNA sequencing strategy to study the activity of the gut microbiome. The new tools analyse transfer RNA (tRNA), a molecular Rosetta Stone that translates the genetic information encoded in DNA into proteins that perform basic biological functions. Developing a clear picture of tRNA dynamics will allow scientists to understand the activity of naturally ...

Akaal Pharma Pty Ltd Announces Licensing Agreement for its First-in-Class, Topical Spingosine-1-Phosphate-1 (S1P1) Receptor Modulator for Atopic Dermatitis and Psoriasis

Akaal Pharma Pty Limited (Akaal Pharma) today announced that it has entered into a licensing agreement for Akaal Pharma’s First-in-Class, topical Spingosine-1-Phosphate-1 (S1P1) modulator, AKP-11, with Boston Pharmaceuticals, Inc. (Boston Pharmaceuticals). AKP-11 is a differentiated S1P1 modulator, which potentially has clinical applications in a number ...

Quidel Receives CE Mark for Point-of-Care Sofia® 2 Lyme+ Fluorescent Immunoassay for Use with Sofia 2 Instrument

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received CE Mark to market Quidel’s Sofia 2 Lyme+ FIA to be used with the Sofia 2 Fluorescent Immunoassay Analyzer for the rapid differential detection of human Ig...

Takeda Announces Listing of American Depositary Shares on the New York Stock Exchange

ADSs Will Trade Under the Ticker Symbol “TAK” NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced that the listing ...

‘I can’t hide my disgust, my disdain’: judge lambasts Michael Flynn – The Guardian

'I can't hide my disgust, my disdain': judge lambasts Michael Flynn The GuardianUS judge delays sentencing of Trump's former security adviser Michael Flynn Evening Standard'You sold your country out': Judge hits out at Trump's former adviser Michael Flynn Sky NewsJonathan Turley: Judge surprises Flynn at sentencing hearing – Here's what to expect next Fox NewsSarah Sanders dodges Trump Found...

ARANZ Medical Raises NZ$5mil New Equity Financing

CHRISTCHURCH, New Zealand, Dec. 18, 2018 /PRNewswire/ -- ARANZ Medical Limited announces the closing of a NZ$5million equity financing. Bruce Davey, ARANZ Medical CEO says, "I'm delighted to announce this investment in our company. Our imaging solutions help improve clinical outcomes for many people with chronic skin conditions, and we are dedicated to delighting our practitioners and patien...

Kindred Healthcare and Netsmart Partner to Create Next Generation Post-Acute Platform

Kindred Healthcare, LLC (“Kindred”) and Netsmart today announced a partnership to create a unique, technology-driven clinical platform that surpasses the traditional boundaries of electronic medical records (“EMRs”) and aligns with the needs of the evolving value-based care environment. Through this partners

Progenra Inc. Receives Therapeutic Pipeline Award from The Michael J. Fox Foundation for Parkinson’s Research and Drug Development

Funding will support Progenra’s development of small molecules for treatment of Parkinson’s Disease Progenra Inc. announces the receipt of a 2018 Therapeutic Pipeline Award from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The award supports Progenra’s program of small molecule drug discovery and development for Parkins...

Not All Stroke Estimates from CHA 2 DS 2 -VASc Scores Are Created Equal

Depending on the patient population used to estimate stroke risks, the threshold score for initiating anticoagulation varies.

DTC Price Disclosure Should Include Cost Sharing Context, Patient Groups Tell CMS

Some patient groups, payers support CMS proposal to require disclosure of list prices in TV ads but want to expand... &#...

MTF Biologics Awards 2018 Extramural Research Grants

World’s largest tissue bank provides $1.6 million in grant funding to advance allograft science, opens applications for 2019 grant program MTF Biologics, the world’s largest tissue bank, today announced that 10 researchers from around the nation have received more than $1.6 million in funding through its 2018 Research Grant Program. “MTF...

Naloxone Mandate In Opioid Labels Divides US FDA Panel, Even As It Wants Patient Conversations

Advisory committee members vote narrowly in favor of labeling opioids with a recommendation to co-prescribe naloxone, but mor...

Naloxone Mandate In Opioid Labels Divides US FDA Panel, Even As They Want Patient Conversations

Advisory committee members vote narrowly in favor of labeling opioids with a recommendation to co-prescribe naloxone, but more agree that...    

First Ever Model for Patient-specific Treatment of Appendix Cancer Developed

NewsResearchers have created a patient-specific tumor 'organoid' model to identify the most effective treatment for each tumor.

New study finds hospitals prescribe more medicines, and more expensive medicines, after joining 340B program

Data and analyses continue to show the 340B program influences prescribing trends at 340B hospitals – ultimately costing patients and our health care system more money. The Government Accountability Office (GAO), for example, conducted an analysis that found per-patient spending at 340B disproportionate share hospital


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks